Chin. J. Org. Chem. ›› 2018, Vol. 38 ›› Issue (6): 1549-1555.DOI: 10.6023/cjoc201801023 Previous Articles     Next Articles



廖世莉a, 张国改a, 曹涵a, 陈碧莹a, 李卫民b, 吴霞a, 冯毅凡a   

  1. a 广东药科大学中心实验室 广州 510000;
    b 广州中医药大学中药学院 广州 510000
  • 收稿日期:2018-01-26 修回日期:2018-02-27 发布日期:2018-03-08
  • 通讯作者: 李卫民,;吴霞,;冯毅凡,;;
  • 基金资助:


Synthesis and Anti-tumor Activities against HepG2 Cell in vitro of the Conjugates of Honokiol, Quercetin and Berberine

Liao Shilia, Zhang Guogaia, Cao Hana, Chen Biyinga, Li Weiminb, Wu Xiaa, Feng Yifana   

  1. a Central Laboratory, Guangdong Pharmaceutical University, Guangzhou 510000;
    b College of Chinese Materia Medica, Guangzhou University of Chinese Medicine, Guangzhou 510000
  • Received:2018-01-26 Revised:2018-02-27 Published:2018-03-08
  • Contact: 10.6023/cjoc201801023;;
  • Supported by:

    Project supported by the National Natural Science Foundation of China (Nos. 21275036, 81202429).

Berberine, honokiol, quercetin are the lead compounds with outstanding anti-tumor activities. Three novel products were synthesized from honokiol, quercetin and berberine. The structures of the products were firstly confirmed by 1H NMR, 13C NMR, 2D NMR, HRMS, IR and UV. All products were evaluated for their anti-tumor activities against HepG2 cell in vitro and the results showed that the inhibitory effects of two compounds on HepG2 cell were far superior to honokiol and berberine hydrochloride, and the anti-tumor activities were similar to the reference drug cisplatin. It means that compounds 1 and 2 are expected to be the potential anti-tumor drugs.

Key words: berberine, honokiol, quercetin, anti-tumor activity